VNU to buy IMS Health for $7B

Dutch media giant VNU is buying IMS Health for $7 billion in cash and stock. VNU believes that adding IMS -- a leading provider of pharmaceutical and healthcare information on product use -- will be a good fit with its Nielsen ratings and analysis of consumer packaged goods. Analysts, however, weren't quick to agree, with some noting that IMS may not have all that much available to cut. VNU is paying $11.25 per share, a 16 percent premium over the stock's average trading price over the past 30 days.

- read this story from USA Today

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.